UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report: August 3, 2006

Date of earliest event reported: July 28, 2006

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other Jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 573-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

[ ] Written communication pursuant to Rule 425 under the Securities Act (17

CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17

CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Item 1.01

Entry into a Material Definitive Agreement

On July 28, 2006, the Board of Directors of

Pfizer Inc. ( Pfizer or the Company ) named

Jeffrey B. Kindler Pfizer s Chief Executive Officer effective July

31, 2006. He succeeds Henry A. McKinnell, who will remain Pfizer s

Chairman of the Board of Directors (the Board ) until February

28, 2007, at which time Dr. McKinnell will retire from the Board. Mr.

Kindler has been elected to the Board effective July 31, 2006. A copy

of the press release announcing the change in the Chief Executive Officer

position is attached hereto as Exhibit 99 and is incorporated herein by

reference.

On July 28, 2006, the Compensation Committee of the Board approved new

compensation arrangements for Mr. Kindler. In connection with Mr. Kindler s

promotion to Chief Executive Officer, his base salary was increased from

$947,500 to $1,350,000 and his target annual bonus under the Company s

Executive Annual Incentive Plan was increased from 65% to 150% of base

salary. The Compensation Committee also approved the grant to Mr. Kindler

of an option to purchase 500,000 shares of Pfizer common stock under Pfizer s

2004 Stock Plan at an exercise price of $26.29 per share, the fair market

value of the Pfizer common stock on July 31, 2006. (Special grants are

typically granted at the end of the month of approval with an exercise

price set at the average of the highest and lowest trading price on the

date of grant.) The option will become exercisable upon the fifth anniversary

of the date of grant, provided, however, that the option may not be exercised

unless and until the average closing price of Pfizer common stock for

20 consecutive trading days exceeds 150% of the exercise price. In addition,

the Compensation Committee determined that any amount earned under any

currently outstanding performance-contingent share and performance-share

awards held by Mr. Kindler would be settled through an award of restricted

stock units if the Company s actual total shareholder return achieved

with respect to such award is less than the median total shareholder return

of the Company s pharmaceutical peer group. The restricted stock

units will vest and become payable in shares of Pfizer common stock if

and when the Company s three year total shareholder return based

on the rolling average over a three calendar year period (current calendar

year plus two prior calendar years) exceeds the median for the pharmaceutical

peer group which is described in Pfizer s Definitive Proxy Statement

filed on March 6, 2006. Upon his retirement or other termination of employment,

any unvested restricted stock units will be forfeited. Mr. Kindler and

his spouse and dependent children will be required to use aircraft provided

by the Company for air travel for security reasons.

Item 5.02

Departure of Directors or Principal Officers; Election of Directors;

Appointment of Principal Officers

On July 28, 2006, the Board named Jeffrey B.

Kindler Pfizer s Chief Executive Officer effective July 31, 2006.

Mr. Kindler succeeds Henry A. McKinnell as Chief Executive Officer. Dr.

McKinnell will continue to serve as Pfizer s Chairman of the Board

until February 28, 2007.

On July 28, 2006, Mr. Kindler was appointed to the Board effective July

31, 2006. Mr. Kindler was also named Chairman of the Executive Committee

of the Board.

Biographical and Other Information Regarding Mr. Kindler

Mr. Kindler, 51, joined Pfizer in 2002 as senior vice president and general

counsel. He became executive vice president and general counsel in 2004

and vice chairman and general counsel in 2005, leading both the legal

and corporate affairs divisions. Prior to joining Pfizer, Mr. Kindler

served as chairman and chief executive officer of Boston Market Corporation,

owned by McDonald s, and president of Partner Brands, also owned

by McDonald s. He was executive vice president, corporate relations

and general counsel of McDonald s from 1997 to 2001, and from 1996

to 1997 served as that company s senior vice president and general

counsel.

Prior to McDonald s, Mr. Kindler was vice president and senior counsel

for litigation and legal policy for General Electric. A former partner

at the Washington law firm of Williams & Connolly, Mr. Kindler also

served as a law clerk to U.S. Supreme Court Justice William J. Brennan,

Jr. and to Judge David L. Bazelon of the U.S. Court of Appeals for the

D.C. Circuit. He also worked at the Federal Communications Commission.

Mr. Kindler earned his B.A. degree, summa cum laude, from Tufts University

in 1977 and J.D. degree, magna cum laude, from Harvard Law School in 1980,

where he served as an editor of the Harvard Law Review.

The material terms of the compensatory arrangements with Mr. Kindler are

described in Item 1.01 of this Form 8-K and are incorporated herein by

reference.

Departure of Dr. McKinnell

The Company is currently negotiating the definitive terms of Dr. McKinnell s

departure as a principal officer. The Company currently expects that any

amounts and benefits payable to Dr. McKinnell as a result of such negotiations

will not exceed the amounts and benefits he would be entitled to receive

under his employment agreement as if he were terminated without cause

as of February 28, 2007. The Company is in the process of reviewing and

quantifying such amounts and benefits. The material terms of Dr. McKinnell s

employment agreement are described in Pfizer s Definitive Proxy

Statement filed on March 16, 2006 and such description is incorporated

herein by reference. The Company will disclose the definitive terms of

Dr. McKinnell s departure as principal officer in a subsequent filing

on Form 8-K.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit 99

Press Release of Pfizer Inc., dated July 28, 2006

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

Margaret M. Foran

Title: Senior Vice President-Corporate

Governance, Associate General Counsel and Corporate Secretary

Dated: August 3, 2006

EXHIBIT INDEX

Exhibit No.

Description

99

Press Release of Pfizer Inc., dated July 28, 2006.